1
|
Gupte M, Umbarkar P, Singh AP, Zhang Q, Tousif S, Lal H. Deletion of Cardiomyocyte Glycogen Synthase Kinase-3 Beta (GSK-3β) Improves Systemic Glucose Tolerance with Maintained Heart Function in Established Obesity. Cells 2020; 9:cells9051120. [PMID: 32365965 PMCID: PMC7291092 DOI: 10.3390/cells9051120] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/02/2020] [Revised: 04/24/2020] [Accepted: 04/27/2020] [Indexed: 01/12/2023] Open
Abstract
Obesity is an independent risk factor for cardiovascular diseases (CVD), including heart failure. Thus, there is an urgent need to understand the molecular mechanism of obesity-associated cardiac dysfunction. We recently reported the critical role of cardiomyocyte (CM) Glycogen Synthase Kinase-3 beta (GSK-3β) in cardiac dysfunction associated with a developing obesity model (deletion of CM-GSK-3β prior to obesity). In the present study, we investigated the role of CM-GSK-3β in a clinically more relevant model of established obesity (deletion of CM-GSK-3β after established obesity). CM-GSK-3β knockout (GSK-3βfl/flCre+/-) and controls (GSK-3βfl/flCre-/-) mice were subjected to a high-fat diet (HFD) in order to establish obesity. After 12 weeks of HFD treatment, all mice received tamoxifen injections for five consecutive days to delete GSK-3β specifically in CMs and continued on the HFD for a total period of 55 weeks. To our complete surprise, CM-GSK-3β knockout (KO) animals exhibited a globally improved glucose tolerance and maintained normal cardiac function. Mechanistically, in stark contrast to the developing obesity model, deleting CM-GSK-3β in obese animals did not adversely affect the GSK-3αS21 phosphorylation (activity) and maintained canonical β-catenin degradation pathway and cardiac function. As several GSK-3 inhibitors are in the trial to treat various chronic conditions, including metabolic diseases, these findings have important clinical implications. Specifically, our results provide critical pre-clinical data regarding the safety of GSK-3 inhibition in obese patients.
Collapse
Affiliation(s)
- Manisha Gupte
- Division of Cardiovascular Medicine, Vanderbilt University Medical Center, Nashville, TN 37232, USA; (M.G.); (P.U.); (A.P.S.); (Q.Z.)
- Department of Biology, Austin Peay State University, Clarksville, TN 37044, USA
| | - Prachi Umbarkar
- Division of Cardiovascular Medicine, Vanderbilt University Medical Center, Nashville, TN 37232, USA; (M.G.); (P.U.); (A.P.S.); (Q.Z.)
- Division of Cardiovascular Disease, UAB|University of Alabama at Birmingham, Birmingham, AL 35294-1913, USA;
| | - Anand Prakash Singh
- Division of Cardiovascular Medicine, Vanderbilt University Medical Center, Nashville, TN 37232, USA; (M.G.); (P.U.); (A.P.S.); (Q.Z.)
- Division of Cardiovascular Disease, UAB|University of Alabama at Birmingham, Birmingham, AL 35294-1913, USA;
| | - Qinkun Zhang
- Division of Cardiovascular Medicine, Vanderbilt University Medical Center, Nashville, TN 37232, USA; (M.G.); (P.U.); (A.P.S.); (Q.Z.)
- Division of Cardiovascular Disease, UAB|University of Alabama at Birmingham, Birmingham, AL 35294-1913, USA;
| | - Sultan Tousif
- Division of Cardiovascular Disease, UAB|University of Alabama at Birmingham, Birmingham, AL 35294-1913, USA;
| | - Hind Lal
- Division of Cardiovascular Medicine, Vanderbilt University Medical Center, Nashville, TN 37232, USA; (M.G.); (P.U.); (A.P.S.); (Q.Z.)
- Division of Cardiovascular Disease, UAB|University of Alabama at Birmingham, Birmingham, AL 35294-1913, USA;
- Correspondence: ; Tel.: (205)-996-4219; Fax: (205)-975-5104
| |
Collapse
|